http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-073548-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e4d121c7abfaaeb49b0e383527ade50a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H13-04 |
| filingDate | 2009-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-073548-A1 |
| titleOfInvention | COMPOUNDS DERIVED FROM DIAZOL AND TRIAZOL, COMPOSITIONS AND USE OF THE SAME TO MODULATE URIC ACID LEVELS |
| abstract | Useful compounds in the modulation of blood uric acid levels, formulations containing them and methods for making and using them are described herein. In some embodiments, a compound described herein is used in the treatment or prevention of diseases related to aberrant levels of uric acid. Claim 1: A compound of the formula (1) or a metabolite, pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, characterized in that: T is N or CH; W is O, S, S (O), S (O) 2, NH, N (alkyl), CH2, CH2O, CH2S or CH2NH; R1 is H, F, Cl, Br, I, -CH2F, -CF2H, -CF3, -CN, -OH, -NO2, -NH2, -NH (alkyl), -N (alkyl) (alkyl), -SO2CH3 , -SO2NH2, -SO2NHCH3, -CO2-alkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, optionally substituted S-alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted aryl or optionally substituted heteroaryl; a is 0, 1 or 2; Ra is H or C1-3 alkyl; Ra 'is H or C1-3 alkyl; or Ra and Ra 'together with the carbon atom to which they are attached form an optionally substituted 3, 4, 5 or 6-membered ring, optionally comprising 1 or 2 heteroatoms selected from O, N and S; Rb, Rc, Re, and Rf are each independently H, F, Cl, Br, I, CF3, CN, alkyl, cycloalkyl, cyclopropylmethyl, NH2, NHR ', NR'R' ', OH, OR', SH, SR ', C (O) R', CO2H, COOR ', CONH2, CONHR', CONR'R '', SO3H, S (O) 2R ', S (O) 2NH2, S (O) 2NHR', S ( O) 2NR'R '', aryl, heterocyclyl or heteroaryl; Rd is H, F, Cl, Br, I, CF3, CN, NH2, NHR ', NR'R' ', OH, OR', SH, SR ', C (O) R', CO2H, COOR ', CONH2 , CONHR ', CONR'R' ', SO3H, S (O) 2R', S (O) 2NH2, S (O) 2NHR ', S (O) 2NR'R' ', aryl, heterocyclyl or heteroaryl; R 'is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or phenyl; R '' is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or phenyl; R 'and R' 'together with the nitrogen atom to which they bind form a saturated or unsaturated, optionally substituted 4, 5 or 6-membered heterocyclic ring; or Rb and Rc, or Rc and Rd, or Rd and Re, or Re and Rf together with the two carbon atoms to which they bind, form an optionally substituted aromatic or non-aromatic 5, 6 or 7-membered ring, which optionally comprises 1 or 2 heteroatoms selected from O, N and S; and wherein the optional substituents are each independently F, Cl, Br, I, CF3, CN, alkyl, cycloalkyl, cyclopropylmethyl, NH2, NHR ', NR'R' ', OH, OR', SH, SR ', C (O) R ', CO2H, COOR', CONH2, CONHR ', CONR'R' ', SO3H, S (O) 2R', S (O) 2NH2, S (O) 2NHR ', S (O) 2NR' R '', aryl, heterocyclyl or heteroaryl; x is 0 or 1; y is 0 or 1; z is 0 or 1; Rx, Rx ', Ry, Ry', Rz and Rz 'are each independently H, F, Cl, Br, I or C1-3 alkyl; or Rx and Rx ', or Ry and Ry', or Rz and Rz ', or Rx and Ry, or Ry and Rz, or Rx and Rz together with the carbon atoms to which they bind, form a 3- ring 7 optionally substituted non-aromatic members, optionally comprising 1 or 2 heteroatoms selected from O, N and S; A is H, C (O) O-B1 or C (O) NH-B2; wherein B1 is H, optionally substituted C1-6 alkyl or a pharmaceutically acceptable cation; B2 is H or optionally substituted C1-6 alkyl. |
| priorityDate | 2008-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.